Fusions

Summaries of gene fusions and their clinical relevance.

Back to Open Access Summaries
Need updated, customized, evidence‑backed summaries? Get it from the leaders in AI‑powered, evidence‑backed summaries provider.
Contact us
Fusion Disease Driver/Marker Power Therapeutic Actionability Prognostic Impact Diagnostic Specificity Monitoring Utility Actions
ROS1–KLC1
(HGNC:10261, HGNC:6387)
MONDO:0021637
(MONDO:0021637)
 moderate moderate weak moderate weak
ROS1–FGFR2
(HGNC:10261, HGNC:3689)
MONDO:0019087
(MONDO:0019087)
 moderate moderate weak moderate weak
ROS1–ALK
(HGNC:10261, HGNC:427)
non-small cell lung carcinoma
(MONDO_0005233)
 weak weak weak weak weak
ROS1–SLC12A2
(HGNC:10261, HGNC:10911)
MONDO:0005233
(MONDO:0005233)
 strong strong moderate strong weak
ROS1–EZR
(HGNC:10261, HGNC:12691)
non-small cell lung carcinoma
(MONDO_0005233)
 strong strong moderate strong weak
ROS1–ZCCHC8
(HGNC:10261, HGNC:25265)
non-small cell lung carcinoma
(MONDO_0005233)
 strong weak weak moderate weak
MEF2D–BCL9
(HGNC:6997, HGNC:1008)
MONDO:0004967
(MONDO:0004967)
 strong moderate strong moderate weak
BCR–PDGFRA
(HGNC:1014, HGNC:8803)
MONDO:0018905
(MONDO:0018905)
 strong strong moderate strong weak
BCL6–BCL2
(HGNC:1001, HGNC:990)
MONDO:0018906
(MONDO:0018906)
 weak weak weak weak weak
BCR–FGFR1
(HGNC:1014, HGNC:3688)
MONDO:0011996
(MONDO:0011996)
 strong moderate moderate strong weak
RHCE–RHD
(HGNC:10008, HGNC:10009)
weak weak weak weak weak
BCL6–IGH
(HGNC:1001, HGNC:5477)
MONDO:0044778
(MONDO:0044778)
 strong moderate moderate strong weak
Showing 501–512 of 512